Home   >  
MAPK Pathway
  >  
p38 MAPK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

p38 MAPK

Chemical Structure Cat. No. Product Name CAS No.
SB 203580 hydrochloride Chemical Structure
 BCP29070 SB 203580 hydrochloride 869185-85-3
SB 203580 hydrochloride is a widely used p38 MAPK inhibitor. SB 203580 hydrochloride (RWJ 64809 hydrochloride) inhibits SAPK2a/p38 and SAPK2b/p38β2, with IC50s of 50 nM and 500 nM, respectively. LCK, GSK3β and PKBα are also inhibited by SB 203580 hydrochloride, but the IC50s are 100-500-fold higher than that for SAPK2a/p38.
LY2322600 Chemical Structure
 BCP27665 LY2322600 862505-01-9
LY2228820 is a novel and potent p38MAPK inhibitor.
MW-150 dihydrochloride dihydrate Chemical Structure
 BCP30837 MW-150 dihydrochloride dihydrate 1661020-92-3
MW-150 dihydrochloride dihydrate is a selective inhibitor of p38αMAPK isoform with a Ki of 101 nM.
ITX-5061 HCl Chemical Structure
 BCP30784 ITX-5061 HCl 1252679-52-9
ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1).
Pexmetinib Chemical Structure
 BCP28410 Pexmetinib 945614-12-0
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.
SD-06 Chemical Structure
 BCP21625 SD-06 271576-80-8
SD-06 is a MAPK p38 alpha inhibitor for the treatment of arthritis.
SB202190 HCl Chemical Structure
 BCP21617 SB202190 HCl 350228-36-3
SB 202190 inhibits p38 and p38β2 with IC50 values of 50 nM and 100 nM. respectively.
R1487 Chemical Structure
 BCP29574 R1487 449811-92-1
R1487 is a p38 MAP kinase inhibitor with an IC50 of 10nM.
UM164 Chemical Structure
 BCP29207 UM164 903564-48-7
UM164 is a movel potent, dual c-Src/p38 with Kd of 2.7 nM (c-Src), potently inhibits both p38α and p38β; inhibits c-Src autophosphorylation in TNBC cell lines.
VX 702 Chemical Structure
 BCP28564 VX 702 745833-23-2
VX-702, one of a series of second-generation, is an orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases.
123下一页末页共 34 条记录 1 / 4 页 
0086-15971444841